Clinical Scorecard: Outcomes and Clinical Progression of COVID-19 in Patients Undergoing Hematopoietic Cell Transplantation: A Regional Analysis from the Middle East
At a Glance
Category
Detail
Condition
COVID-19 infection in hematopoietic cell transplant (HCT) recipients
Key Mechanisms
SARS-CoV-2 infection causing respiratory tract involvement, with potential progression to pneumonia and acute respiratory distress syndrome, especially severe in immunocompromised HCT patients
Target Population
Post allogeneic or autologous hematopoietic cell transplant recipients of any age
Care Setting
Tertiary care hematopoietic cell transplant centers in the Middle East
Key Highlights
COVID-19 severity in HCT patients assessed by hospital admission, WHO severity stage, ICU admission, oxygen requirement, mechanical ventilation, and mortality.
Risk factors analyzed include age, sex, BMI, transplant type and number, conditioning regimen, immunosuppression status, underlying disease status, prophylactic antimicrobials, time from transplant to COVID-19, and comorbidities.
Among 91 HCT patients with COVID-19, median age was 35 years, 57% had allogeneic HCT, 43% autologous, and 48% had prior comorbidities; 86% were symptomatic with fever, cough, or shortness of breath.
Guideline-Based Recommendations
Diagnosis
Laboratory confirmation of COVID-19 by nasal or oropharyngeal swab PCR testing is required for diagnosis in HCT recipients.
Management
COVID-19 directed therapies were administered to approximately half of the patients; management should consider severity and individual patient risk factors.
Monitor and manage immunosuppression carefully given the vulnerability of HCT patients.
Monitoring & Follow-up
Regular monitoring of clinical symptoms and laboratory parameters including WBC, lymphocyte count, neutrophil count, platelet count, ferritin, ESR, CRP, and albumin levels.
Chest X-ray imaging to detect pulmonary involvement.
Serial PCR and serology testing every 7 days to assess viral clearance and antibody development.
Risks
HCT recipients are at increased risk of severe COVID-19 due to immunosuppression and prior lung complications.
Presence of comorbidities, active graft-versus-host disease, and immunosuppressive therapy may worsen outcomes.
Patient & Prescribing Data
91 post-HCT patients diagnosed with COVID-19 from ten Middle East centers, median age 35 years, mixed allogeneic and autologous transplants.
48% received COVID-19 directed therapies; 52% did not. Majority were on prophylactic antimicrobials and/or immunosuppressive medications at time of infection.
Clinical Best Practices
Confirm COVID-19 diagnosis with PCR testing in all suspected HCT patients.
Assess severity using WHO classification and composite endpoints including ICU admission and need for mechanical ventilation.
Evaluate risk factors such as comorbidities, immunosuppression, and time from transplant to infection to guide management.
Perform regular laboratory and radiologic monitoring to detect disease progression.
Consider individualized COVID-19 directed therapies based on severity and patient risk profile.
Monitor viral clearance and antibody response with serial PCR and serology testing.
by Riad El Fakih, Alfadil Haroon, Feras Alfraih, Murtadha K. Al-Khabori, Mohsen Alzahrani, Ahmad Alhuraiji, Abdulaziz Hamadah, Naif I. AlJohani, Bader Alahmari, Mohammed F. Essa, Ibraheem H. Motabi, Imran K. Tailor, Reem S. Almaghrabi, Khalil Al-Farsi, Ibraheem Abosoudah, Mouhab Ayas, Tusneem A. Elhassan, Ashraf M. Suhebeh, Syed Osman Ahmed, Saud Alhayli, Panayotis Kaloyannidis, Ahmad Alsaeed, Khalid Al Anezi, Sameer Alamoudi, Moussab Damlaj, Hani Al Hashmi, Mahmoud Aljurf
